| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0005 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0007 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.18 | 0.0007 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.16 | 0.0008 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0009 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0009 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |